Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis - Full Text View

Sponsors and Collaborators:	University of Michigan Renal Research Institute
Information provided by:	University of Michigan
ClinicalTrials.gov Identifier:	NCT00242164

Purpose

The study is being performed to better understand dialysis techniques which keep heart functions stable during dialysis. People on dialysis have a high risk for heart disease and strokes. More information about dialysis techniques that keep hearts stable may help prevent the high risk of cardiovascular disease and death and help to reduce discomfort during dialysis. In this study we are looking at the way that the magnesium in dialysate affects heart function during dialysis. High or low levels of magnesium may change the way hearts beat. We want to know if lowering the amount of magnesium in dialysate will affect the amount of magnesium in blood or change the heart beat.

Condition	Intervention	Phase
Hemodialysis Chronic Kidney Disease Arrhythmia	Drug: Dialysate Magnesium (Concentration)	Phase II

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Active Control, Crossover Assignment, Efficacy Study
Official Title:	Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis

Resource links provided by NLM:

Genetics Home Reference related topics: Brugada syndrome short QT syndrome

MedlinePlus related topics: Arrhythmia Dialysis Kidney Failure

Drug Information available for: Magnesium

U.S. FDA Resources

Further study details as provided by University of Michigan:

Primary Outcome Measures:

The primary outcome is the difference in QT dispersion between low dialysate magnesium and normal dialysate magnesium

Estimated Enrollment:	25
Study Start Date:	November 2005
Estimated Study Completion Date:	November 2006

Detailed Description:

Heart disease is a major cause of illness and death among patients on dialysis. Changes in the heart's rhythm and sudden cardiac death are also important problems in this group. Abnormal rhythm can occur during hemodialysis.

During dialysis, the blood comes in contact with a solution called dialysate. This solution contains minerals like calcium, potassium and magnesium. Some studies have indirectly suggested that lower magnesium in dialysis patients protects them from having rhythm problems.

Factors that increase the chance for the development of abnormal rhythms can be indirectly assessed by evaluating the electrocardiogram (EKG). This is done by measuring the distance between the wave forms on the EKG. One of these is called the QT interval. QT dispersion is a value derived from the QT interval. A long QT interval is thought to make an individual more prone to having abnormal heart rhythms.

Therefore we plan to study the effect of low levels of magnesium in the dialysate on QT interval and dispersion and the tendency for rhythm change. We will compare QT interval changes during dialysis with low magnesium with QT interval changes during dialysis with normal magnesium.

This will be a cross over trial including 24 adult male and female patients on chronic hemodialysis. Subjects will be studied during two of their regular dialysis sessions, the only difference being the amount of magnesium in the dialysate. QT interval and QT dispersion will be calculated from the EKG recordings before and after each dialysis session.

The results of this study will lead to a better understanding of cardiovascular risks in patients undergoing chronic dialysis and may offer a potentially novel strategy to reduce the risk of abnormal heart rhythms risk during dialysis.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

18 years of age and over with end-stage renal disease. (ESRD)
have been on maintenance hemodialysis therapy three times/week for greater than or equal to 3 months
All causes of renal failure are included

Exclusion Criteria:

less than 18 years of age
have been on maintenance hemodialysis therapy three times/week for less than 3 months
are pregnant or lactating
unable or unwilling to provide informed consent
currently participating in a clinical trial with an intervention
systolic (top number) blood pressure levels greater than or equal to 180 or less then 80
diastolic (bottom number) blood pressure levels greater than 110
a hemoglobin level (red blood cell measure) that is less than 8mg/dl
a corrected calcium level that is greater than 11mg/dl or less than 8mg/dl
had a change in their anti-hypertensive medications within the last three weeks
clinical signs and symptoms of untreated or unresolved infection
clinical evidence requiring admission to the hospital
had a cerebral vascular accident or myocardial incident within the past 3 months
Based on the assessment of the investigators, or study coordinator designee, patients who appear unlikely or unable to participate in the required study procedures
Patients with a history of arrhythmias, recent electrophysiological evaluation and or having pacemakers are excluded.
Patients with acute renal failure.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00242164

Contacts

Contact: Kathryn M Lindblad, RN, MBA

734-764-5187

lindblad@umich.edu

Locations

United States, Michigan
University of Michigan Dialysis Center
Ann Arbor, Michigan, United States, 48104
University of Michigan Dialysis Center
Livonia, Michigan, United States, 48152

Sponsors and Collaborators

University of Michigan

Renal Research Institute

Investigators

Principal Investigator:

Panduranga S Rao, MD, DNB, MS

University of Michigan

More Information

Additional Information:

Dr. Panduranga Rao's University of Michigan webpage This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	DRDA 05-2076
Study First Received:	October 17, 2005
Last Updated:	October 17, 2005
ClinicalTrials.gov Identifier:	NCT00242164 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Michigan:

Hemodialysis
Magnesium
Arrhythmia
QTc interval
QT dispersion

Study placed in the following topic categories:

Renal Insufficiency
Heart Diseases
Urologic Diseases
Renal Insufficiency, Chronic

Kidney Failure, Chronic
Kidney Diseases
Kidney Failure
Arrhythmias, Cardiac

Additional relevant MeSH terms:

Renal Insufficiency
Pathologic Processes
Heart Diseases
Urologic Diseases
Renal Insufficiency, Chronic

Kidney Failure, Chronic
Cardiovascular Diseases
Kidney Diseases
Kidney Failure
Arrhythmias, Cardiac

ClinicalTrials.gov processed this record on September 10, 2009